Reviewer's report

Title: Understanding fatigue during hepatitis C virus treatment: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

Version: 2  Date: 8 December 2013

Reviewer: Jean-Christophe OUALLET

Reviewer's report:

Discretionary revisions to consider:

1. The authors may clarify the following sentence at the end of the results section: "Higher mean change from baseline in EQ-5D VAS scores observed for the placebo arm reflect the higher proportion of placebo-treated patients who were no longer on placebo treatment because they met virology stopping rules that indicated treatment failure." With reference to figure 4b?

2. In the discussion, page 16, Line 4: "A lower on-treatment disutility was observed in the simeprevir group compared with the PR group." Is it possible to clarify what does that mean?

3. Details of efficacy data should not be in this manuscript as data are published elsewhere (Table 2).

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests